GSK settles two California lawsuits related to heartburn drug Zantac
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any liability in ...
Boehringer Ingelheim faces second hung jury in Chicago Zantac trial
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
BioWorld2d
Boehringer Ingelheim divulges new NOX4 inhibitors
Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...
ENDPOINTS NEWS5d
Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta
A Phase 3 trial investigating Boehringer Ingelheim’s nerandomilast in idiopathic pulmonary fibrosis hit its primary endpoint, ...
Weight-loss market to see 16 new drugs by 2029, report estimates
The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently ...
health.economictimes.indiatimes12d
GenAI can turbocharge lifesciences growth if choices are selective, deliberate: HFS Research
The report is based on insights from multiple interviews of global lifesciences leaders about their GenAI journey, primary ...
Pharmabiz15d
HFS Research with Indegene notes strategic GenAI adoption to revolutionize lifesciences sector
HFS Research with Indegene notes strategic GenAI adoption to revolutionize lifesciences sector: Our Bureau, Bengaluru Friday, September 6, 2024, 17:10 Hrs [IST] HFS Research has r ...